Progressive and Sustained Disease Control in Patients With Atopic Dermatitis (AD) Aged 12–17 Years Treated With Tralokinumab for 52 Weeks. J of Skin 2024, 8 (2), s377. https://doi.org/10.25251/skin.8.supp.377.